Enoximone
 | |
| Clinical data | |
|---|---|
| Trade names | Perfan |
| AHFS/Drugs.com | International Drug Names |
| Routes of administration | Intravenous |
| ATC code | |
| Legal status | |
| Legal status |
|
| Pharmacokinetic data | |
| Bioavailability | 50% (oral) |
| Protein binding | 85% |
| Metabolism | Liver (oxidation) |
| Elimination half-life | 4 to 10 hours |
| Excretion | Renal (60 to 70%) |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| DrugBank | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEMBL | |
| CompTox Dashboard (EPA) | |
| Chemical and physical data | |
| Formula | C12H12N2O2S |
| Molar mass | 248.30 g·mol−1 |
| 3D model (JSmol) | |
| Melting point | 255 to 258 °C (491 to 496 °F) (decomposes) |
| |
| |
| (verify) | |
Enoximone (INN, trade name Perfan) is an imidazole phosphodiesterase inhibitor. It is used in the treatment of congestive heart failure and is selective for phosphodiesterase 3.[1]
Synthesis
Prepn: BE 883856 (1980 to Richardson-Merrell); R. A. Schnettler et al., U.S. patent 4,405,635 (1983 to Merrell-Dow)
References
- ^ Boldt J, Suttner S (September 2007). "Combined use of ultra-short acting beta-blocker esmolol and intravenous phosphodiesterase 3 inhibitor enoximone". Expert Opin Pharmacother. 8 (13): 2135–47. doi:10.1517/14656566.8.13.2135. PMID 17714066. S2CID 46021219.
- ^ Schnettler, Richard A.; Dage, Richard C.; Grisar, J. Martin (1982). "4-Aroyl-1,3-dihydro-2H-imidazol-2-ones, a new class of cardiotonic agents". Journal of Medicinal Chemistry. 25 (12): 1477–1481. doi:10.1021/jm00354a017. ISSN 0022-2623. PMID 7154009.
External links
Media related to Enoximone at Wikimedia Commons
 | This drug article relating to the cardiovascular system is a stub. You can help Wikipedia by expanding it. |